Page last updated: 2024-11-07

cp 66713

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CP 66713: adenosine receptor antagonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID124473
CHEMBL ID303198
SCHEMBL ID6905148
MeSH IDM0195508

Synonyms (20)

Synonym
cp-66713
CHEMBL303198 ,
91896-57-0
8-chloro-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxalin-4-amine
cp 66713
bdbm50004571
8-chloro-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxalin-4-ylamine
HMS3262F06
SCHEMBL6905148
(1,2,4)triazolo(4,3-a)quinoxalin-4-amine, 8-chloro-1-phenyl-
cp-66713 mesylate salt
91896-58-1
CCG-222206
NCGC00261587-01
tox21_500902
8-chloro-1-phenyl-(1,2,4)triazolo(4,3-a)quinoxalin-4-amine
DTXSID80238743
cp-66713, >=98% (hplc)
4-amino-8-chloro-1-phenyl-[1,2,4]triazolo[4,3-a]quinoxaline
AKOS040751257
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.29850.001530.607315,848.9004AID1224821
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)IC50 (µMol)0.27000.00020.552110.0000AID31403
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki0.27000.00011.20929.9700AID32177; AID32192
Adenosine receptor A2bRattus norvegicus (Norway rat)IC50 (µMol)0.02100.00240.68169.0000AID33406
Adenosine receptor A2aRattus norvegicus (Norway rat)IC50 (µMol)0.02100.00120.48289.0000AID33406
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki0.02100.00021.494010.0000AID33931
Adenosine receptor A1Cavia porcellus (domestic guinea pig)Ki6.90000.00030.45466.9000AID32292
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A2bRattus norvegicus (Norway rat)Ratio0.02100.00330.82929.6000AID33746
Adenosine receptor A2aRattus norvegicus (Norway rat)Ratio0.02100.00330.82309.6000AID33746
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Molecular Functions (1)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID33746Binding affinity against adenosine A2 receptor using [3H]- NECA as radioligand1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID33586Binding affinity towards adenosine A2 receptor in rat striatal membranes using N-[3H]-ethyladenosin-5''-uronamide as radioligand1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID31403Binding affinity towards the adenosine A1 receptor in cerebral cortices of Sprague-Dawley male rats using [3H]CHA as radioligand.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID184683Minimal effective dose in an rat anti-immobility effect using behavioral despair test1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID189937Ratio of urinary excretion value (urinary volume) in treated rats to that in control rats, at a peroral dose of 25 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID33752Ratio of A2 to A1.1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID32348Tested for the displacement [3H]PIA from Adenosine A1 receptor in rat brain membrane1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Tetrahydrobenzothiophenone derivatives as a novel class of adenosine receptor antagonists.
AID33587Binding affinity against adenosine A2 receptor in rat striatal membranes using N-[3H]-ethyladenosin-5''-uronamide as radioligand in the presence of 50 nM cyclopentyladenosine1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID188116Effect on urinary excretion potassium and sodium after oral administration of 25 mg/kg to rats(potassium and sodium excretion in control rat is 0.209+/-0.007)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID32292Binding affinity against adenosine A1 receptor in guinea pig forebrain membranes using N6-[3H]cyclohexyladenosine as radioligand1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID32177Binding affinity against adenosine A1 receptor using [3H]-CHA or [3H]PIA as radioligand1992Journal of medicinal chemistry, Feb-07, Volume: 35, Issue:3
Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential.
AID189925Ratio of urinary excretion value (Na+ concentration) in treated rats to that in control rats, at a peroral dose of 25 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID191343Oral diuretic activity was measured after oral administration of 25 mg/kg to rats(control volume is 1.02+/-0.02)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID174518Serum creatinine concentration measured after intraperitoneal administration of 10 mg/kg of compound to rats(vehicle 3.38+/-0.29)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID32192Binding affinity towards adenosine A1 receptor in rat cortical membranes using N6-[3H]cyclohexyladenosine as radioligand1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID192673Percent inhibition of serum creatinine by the compound given as ratio of Cr value in treated to vehicle treated ones after intraperitoneal administration of 10 mg/kg of compound to rats(vehicle 3.38+/-0.29)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID194797Percent inhibition of Urea nitrogen by the compound given as ratio of UN value in treated to vehicle treated ones after intraperitoneal administration of 10 mg/kg of compound to rats(vehicle 114+/-8.7)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID33406Evaluated for the binding affinity towards the Adenosine A2 receptor in corpora striata of rats using [3H]NECA as radioligand.1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
AID188282Ratio of sodium ion/potassium ion concentration in treated rats to that in control rats, at a peroral dose of 25 mg/Kg1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID190186Urea nitrogen concentration measured after intraperitoneal administration of 10 mg/kg of compound to rats(vehicle 114+/-8.7)1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID33931Displacement [3H]-CGS-21,680 from Adenosine A2A receptor in rat striatal membrane.1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Tetrahydrobenzothiophenone derivatives as a novel class of adenosine receptor antagonists.
AID228357Ratio of Ki at A2 receptor to that of A1 receptor1992Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16
Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's16 (72.73)18.2507
2000's2 (9.09)29.6817
2010's2 (9.09)24.3611
2020's2 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.19 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (95.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]